{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:30:53Z","timestamp":1773480653005,"version":"3.50.1"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1016\/s0939-6411(03)00138-3","type":"journal-article","created":{"date-parts":[[2003,9,16]],"date-time":"2003-09-16T22:47:04Z","timestamp":1063752424000},"page":"307-318","source":"Crossref","is-referenced-by-count":189,"title":["Cyclosporine A delivery to the eye: A pharmaceutical challenge"],"prefix":"10.1016","volume":"56","author":[{"given":"F","family":"Lallemand","sequence":"first","affiliation":[]},{"given":"O","family":"Felt-Baeyens","sequence":"additional","affiliation":[]},{"given":"K","family":"Besseghir","sequence":"additional","affiliation":[]},{"given":"F","family":"Behar-Cohen","sequence":"additional","affiliation":[]},{"given":"R","family":"Gurny","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0939-6411(03)00138-3_BIB1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2165\/00003495-199550050-00009","article-title":"Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral)","volume":"50","author":"Noble","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0002-9394(14)76692-9","article-title":"Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis","volume":"112","author":"Nussenblatt","year":"1991","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02230339","article-title":"Relapsing Wegener's granulomatosis: successful treatment with cyclosporin-A","volume":"15","author":"Georganas","year":"1996","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy","volume":"321","author":"Prummel","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s003470050146","article-title":"Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor","volume":"94","author":"Reinhard","year":"1997","journal-title":"Ophthalmologe"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/bjo.74.6.350","article-title":"Ocular penetration of cyclosporin A. III: The human eye","volume":"74","author":"BenEzra","year":"1990","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB8","first-page":"356","article-title":"The side-effects of ciclosporine-A and tacrolimus","volume":"49","author":"Mihatsch","year":"1998","journal-title":"Clin. Nephrol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000063299","article-title":"Colchicine suppresses osteopontin expression and inflammatory cell infiltration in chronic cyclosporine nephrotoxicity","volume":"92","author":"Li","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00467-001-0810-1","article-title":"Cyclosporin-related nephrotoxicity in children with nephrotic syndrome","volume":"17","author":"Ganesan","year":"2002","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/eye.2001.10","article-title":"Topical cyclosporin A in the management of vernal keratoconjunctivitis","volume":"15","author":"Gupta","year":"2001","journal-title":"Eye"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.120.3.330","article-title":"Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine","volume":"120","author":"Kunert","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00003226-200203000-00006","article-title":"Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis","volume":"21","author":"Perry","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00007691-198406000-00002","article-title":"Cyclosporine: experience with therapeutic monitoring","volume":"6","author":"Bowers","year":"1984","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB15","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1021\/jm00076a002","article-title":"Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations","volume":"36","author":"el Tayar","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1016062224568","article-title":"Estimation of the increase in solubility of drugs as a function of bile salt concentration","volume":"13","author":"Mithani","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB17","first-page":"1362","article-title":"Ocular penetration of cyclosporin A. The rabbit eye","volume":"31","author":"BenEzra","year":"1990","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0002-9394(14)70579-3","article-title":"An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis","volume":"121","author":"el Asrar","year":"1996","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2460\/javma.1991.199.08.1039","article-title":"Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs","volume":"199","author":"Olivero","year":"1991","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0002-9394(14)73872-3","article-title":"Local therapy of corneal allograft rejection with cyclosporine","volume":"119","author":"Zhao","year":"1995","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00003226-199309000-00008","article-title":"Topical cyclosporin A in the treatment of anterior segment inflammatory disease","volume":"12","author":"Holland","year":"1993","journal-title":"Cornea"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","article-title":"Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome","volume":"72","author":"Gunduz","year":"1994","journal-title":"Acta Ophthalmol. (Copenh)"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB24","first-page":"650","article-title":"Intraocular penetration of topically applied cyclosporine","volume":"20","author":"Kaswan","year":"1988","journal-title":"Transpl. Proc."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/eye.1997.126","article-title":"A comparative approach to topical cyclosporine therapy","volume":"11","author":"Williams","year":"1997","journal-title":"Eye"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/jop.1991.7.301","article-title":"Safety and tolerability of two percent cyclosporine (Sandimmune) ophthalmic ointment in normal volunteers","volume":"7","author":"Solch","year":"1991","journal-title":"J. Ocul. Pharmacol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1600-0420.1999.770217.x","article-title":"Toxicological evaluation of cyclosporine eyedrops","volume":"77","author":"Knagenhjelm","year":"1999","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9394(00)00625-5","article-title":"Unusual corneal deposit after the topical use of cyclosporine as eyedrops","volume":"130","author":"Kachi","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0378-5173(00)00443-9","article-title":"Increased partitioning of pilocarpine to the oily phase of submicron emulsion does not result in improved ocular bioavailability","volume":"202","author":"Sznitowska","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB30","first-page":"519","article-title":"Pharmacokinetic of topical cyclosporin A in the rabbit eye","volume":"27","author":"Wiederholt","year":"1986","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004170050257","article-title":"Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study","volume":"237","author":"Heiligenhaus","year":"1999","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB32","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2460\/javma.1991.199.08.1043","article-title":"Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs","volume":"199","author":"Morgan","year":"1991","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3109\/02713689209000737","article-title":"Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea","volume":"11","author":"Cheeks","year":"1992","journal-title":"Curr. Eye Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archopht.1985.01050010107030","article-title":"Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum","volume":"103","author":"Mosteller","year":"1985","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bjo.73.8.600","article-title":"Penetration of 2% cyclosporin eyedrops into human aqueous humour","volume":"73","author":"Diaz-Llopis","year":"1989","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB36","first-page":"3080","article-title":"Improved extemporaneous formulation of cyclosporine ophthalmic drops","volume":"51","author":"Mueller","year":"1994","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB37","doi-asserted-by":"crossref","unstructured":"J. Sansom, K.C. Barnett, W. Neumann, A. Schulte-Neumann, B. Clerc, J.P. Jegou, V. Haas, A. Weingarten, Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial. Vet. Rec. 137 (1995) 504\u2013507.","DOI":"10.1136\/vr.137.20.504"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1600-0420.2002.800205.x","article-title":"Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye","volume":"80","author":"Loftsson","year":"2002","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB39","first-page":"3150","article-title":"The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops","volume":"21","author":"Kanai","year":"1989","journal-title":"Transpl. Proc."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB40","first-page":"208","article-title":"Topically applied cyclosporine in azone prolongs corneal allograft survival","volume":"29","author":"Newton","year":"1988","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jps.2600830120","article-title":"Effects of four penetration enhancers on corneal permeability of drugs in vitro","volume":"83","author":"Tang-Liu","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00003226-200107000-00013","article-title":"Effects of three penetration enhancers on transcorneal permeation of cyclosporine","volume":"20","author":"van der Bijl","year":"2001","journal-title":"Cornea"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0939-6411(98)00069-1","article-title":"Ocular tolerance of preservatives on the murine cornea","volume":"47","author":"Furrer","year":"1999","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB44","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1023\/A:1010928025753","article-title":"The mucosal toxicity of different benzalkonium chloride analogues evaluated with an alternative test using slugs","volume":"18","author":"Adriaens","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(01)00907-3","article-title":"Increased corneal hydration induced by potential ocular penetration enhancers: assessment by differential scanning calorimetry (DSC) and by desiccation","volume":"232","author":"Monti","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB46","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"The drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Canc."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB47","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.2042-7158.1996.tb03911.x","article-title":"Improved ocular bioavailability of indomethacin by novel ocular drug carriers","volume":"48","author":"Calvo","year":"1996","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1023\/A:1013671819604","article-title":"Cyclosporine A formulation affects its ocular distribution in rabbits","volume":"19","author":"Kuwano","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB49","series-title":"Handbook of Pharmaceutical Excipients","first-page":"379","article-title":"Polyoxyethylene stearate","author":"Hickok","year":"1994"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000267160","article-title":"A submicron emulsion as ocular vehicle for delta-8- tetrahydrocannabinol: effect on intraocular pressure in rabbits","volume":"24","author":"Muchtar","year":"1992","journal-title":"Ophthalmic Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/jop.1994.10.509","article-title":"Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits","volume":"10","author":"Naveh","year":"1994","journal-title":"J. Ocul. Pharmacol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB52","unstructured":"S. Ding. Non-irritating emulsions for sensitive tissue, U.S. Patent 5,474,979, 1995."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1076\/ceyr.18.2.91.5381","article-title":"Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs","volume":"18","author":"Acheampong","year":"1999","journal-title":"Curr. Eye Res."},{"issue":"2000","key":"10.1016\/S0939-6411(03)00138-3_BIB54","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group [published erratum appears in Ophthalmology 2000 Jul;107(7):1220.]","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1081\/PDT-100102035","article-title":"Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution","volume":"5","author":"Klang","year":"2000","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB56","first-page":"427","article-title":"Ocular delivery of cyclosporine A. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A","volume":"11","author":"Abdulrazik","year":"2001","journal-title":"S. T. P. Pharma Sci."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB57","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0161-6420(93)31558-7","article-title":"Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye","volume":"100","author":"Milani","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-3659(99)00192-3","article-title":"Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption","volume":"63","author":"Law","year":"2000","journal-title":"J. Controlled Rel."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB59","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1016015803611","article-title":"Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A","volume":"13","author":"Calvo","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0378-5173(94)90179-1","article-title":"Study of the mechanism of interaction of poly(E-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy","volume":"103","author":"Calvo","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1076\/ceyr.17.1.39.5251","article-title":"Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat","volume":"17","author":"Juberias","year":"2002","journal-title":"Curr. Eye Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0142-9612(96)00144-5","article-title":"Influence of sterilization processes on poly(E-caprolactone) nanospheres","volume":"18","author":"Masson","year":"1997","journal-title":"Biomaterials"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/02652049709033830","article-title":"Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study","volume":"14","author":"Le Bourlais","year":"1997","journal-title":"J. Microencapsul."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB64","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/02652049109021873","article-title":"Studies on the transport pathway of PBCA nanoparticles in ocular tissues","volume":"8","author":"Zimmer","year":"1991","journal-title":"J. Microencapsul."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(01)00760-8","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A","volume":"224","author":"De Campos","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0378-5173(99)00003-4","article-title":"Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention","volume":"180","author":"Felt","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1097-4636(1999)48:2<111::AID-JBM3>3.0.CO;2-W","article-title":"Effects of dry heat and saturated steam on the physical properties of chitosan","volume":"48","author":"Lim","year":"1999","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00003226-199007000-00003","article-title":"The collagen shield. A new vehicle for delivery of cyclosporin A to the eye","volume":"9","author":"Reidy","year":"1990","journal-title":"Cornea"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/02713689408995775","article-title":"Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields","volume":"13","author":"Pleyer","year":"1994","journal-title":"Curr. Eye Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/jop.1995.11.319","article-title":"Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine","volume":"11","author":"Gebhardt","year":"1995","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB71","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/jop.1995.11.509","article-title":"Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection","volume":"11","author":"Gebhardt","year":"1995","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB72","unstructured":"R. Wenger, M. Mutter, A. Hamel, F. Hubler. Pro-Drug and use thereof as a medicament, WO Patent 02\/085928, 2002."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB73","unstructured":"Meadows D. Nonaqueous fluorinated drug delivery vehicle suspensions, U.S. Patent 5,173,298, 1992."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB74","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0168-3659(01)00441-2","article-title":"Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs","volume":"76","author":"Kawakami","year":"2001","journal-title":"J. Controlled Rel."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB75","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1981.03930020514024","article-title":"Suppression of corneal allograft rejection by cyclosporin A","volume":"99","author":"Salisbury","year":"1981","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/02713689409167297","article-title":"Local efficacy of cyclosporine in corneal transplant therapy","volume":"13","author":"Oh","year":"1994","journal-title":"Curr. Eye Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB77","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00915740","article-title":"Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits","volume":"17","author":"Harper","year":"1993","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB78","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s004170050321","article-title":"Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit","volume":"237","author":"Rojas Silva","year":"1999","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00137133","article-title":"Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection","volume":"12","author":"Alghadyan","year":"1988","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB80","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3109\/02713689508998493","article-title":"A subconjunctivalde gradable implant for cyclosporine delivery in corneal transplant therapy","volume":"14","author":"Apel","year":"1995","journal-title":"Curr. Eye Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB81","first-page":"155","article-title":"Retinal toxicity study of intravitreal cyclosporin","volume":"17","author":"Grisolano","year":"1986","journal-title":"Ophthalmic Surg."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB82","first-page":"3134","article-title":"Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer","volume":"41","author":"Lai","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB83","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00137134","article-title":"Liposome-bound cyclosporine: retinal toxicity after intravitreal injection","volume":"12","author":"Alghadyan","year":"1988","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB84","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00137135","article-title":"Liposome-bound cyclosporine: clearance after intravitreal injection","volume":"12","author":"Alghadyan","year":"1988","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB85","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/00003226-200110000-00015","article-title":"Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer","volume":"20","author":"Xie","year":"2001","journal-title":"Cornea"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB86","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archopht.1992.01080140044023","article-title":"Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device","volume":"110","author":"Sanborn","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archopht.1996.01100130307014","article-title":"Evaluation of a delivery system providing long-term release of cyclosporine","volume":"114","author":"Pearson","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0161-6420(98)91176-9","article-title":"Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis","volume":"105","author":"Jaffe","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/S0939-6411(03)00138-3_BIB89","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/bjo.83.11.1225","article-title":"New developments in sustained release drug delivery for the treatment of intraocular disease","volume":"83","author":"Velez","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB90","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3109\/02713689609000766","article-title":"An intravitreal device providing sustained release of cyclosporine and dexamethasone","volume":"15","author":"Enyedi","year":"1996","journal-title":"Curr. Eye Res."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-5224.2000.00117.x","article-title":"Long-term effect on the equine eye of an intravitreal device used for sustained release of cyclosporine A","volume":"3","author":"Gilger","year":"2000","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0165-2427(00)00219-1","article-title":"Effect of an intravitreal cyclosporine implant on experimental uveitis in horses","volume":"76","author":"Gilger","year":"2000","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB93","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/jop.1991.7.221","article-title":"Cyclosporine: a therapy in inflammatory eye disease","volume":"7","author":"Wakefield","year":"1991","journal-title":"J. Ocul. Pharmacol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB94","first-page":"212","article-title":"Penetrating keratoplasty in the rat: a model for the study of immunosuppressive treatment of graft rejection","volume":"33","author":"Herbort","year":"1989","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/S0939-6411(03)00138-3_BIB95","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0161-6420(96)30636-2","article-title":"Longitudinal tear study after cyclosporine in kidney transplant recipients","volume":"103","author":"Palmer","year":"1996","journal-title":"Ophthalmology"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641103001383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641103001383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T19:21:43Z","timestamp":1704914503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641103001383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S0939641103001383"],"URL":"https:\/\/doi.org\/10.1016\/s0939-6411(03)00138-3","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}